Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.17 is 14% above its 5-year average of 1.02, around the middle of its 5-year range (0.62–1.62).
As of the fiscal period ended Saturday, June 27, 2026. 4.39% above its 12-month average of 1.12.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-27): 1.17.
QUICK RATIO (ACID-TEST)
1.17
QUICK RATIO (ACID-TEST) AVG TTM
1.12
QUICK RATIO (ACID-TEST) AVG 3Y
1.01
QUICK RATIO (ACID-TEST) AVG 5Y
1.02
QUICK RATIO (ACID-TEST) AVG 10Y
1.07
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+4.39%
CURRENT VS 3Y AVG
+15.44%
CURRENT VS 5Y AVG
+13.91%
CURRENT VS 10Y AVG
+9.35%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.15
median of 685 covered companies
CURRENT VS SECTOR MEDIAN
-62.99%
vs the sector median at left
Bioventus Inc.
Market Cap
$896.31M
Quick Ratio (Acid-Test)
1.17
TTM Avg
1.12
3Y Avg
1.01
5Y Avg
1.02
Market Cap
$890.21M
Quick Ratio (Acid-Test)
16.16
TTM Avg
3.88
3Y Avg
3.97
5Y Avg
4.50
Market Cap
$904.17M
Quick Ratio (Acid-Test)
81.42
TTM Avg
11.94
3Y Avg
8.59
5Y Avg
10.34
Market Cap
$914.03M
Quick Ratio (Acid-Test)
1.06
TTM Avg
1.14
3Y Avg
1.09
5Y Avg
1.06
Market Cap
$868.45M
Quick Ratio (Acid-Test)
9.52
TTM Avg
4.26
3Y Avg
6.09
5Y Avg
7.80
Market Cap
$931.08M
Quick Ratio (Acid-Test)
8.79
TTM Avg
12.77
3Y Avg
8.84
5Y Avg
8.84
Market Cap
$843.28M
Quick Ratio (Acid-Test)
4.03
TTM Avg
6.29
3Y Avg
5.71
5Y Avg
7.79
Market Cap
$951.98M
Quick Ratio (Acid-Test)
11.36
TTM Avg
7.20
3Y Avg
7.20
5Y Avg
7.20
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bioventus Inc. (BVS) | $896.31M | 1.17 | 1.12 | 1.01 | 1.02 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $890.21M | 16.16 | 3.88 | 3.97 | 4.50 |
| Arbutus Biopharma Corp (ABUS)vs › | $904.17M | 81.42 | 11.94 | 8.59 | 10.34 |
| HealthStream, Inc. (HSTM)vs › | $914.03M | 1.06 | 1.14 | 1.09 | 1.06 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $868.45M | 9.52 | 4.26 | 6.09 | 7.80 |
| CeriBell, Inc. (CBLL)vs › | $931.08M | 8.79 | 12.77 | 8.84 | 8.84 |
| Alumis Inc. (ALMS)vs › | $844.89M | 6.74 | 5.17 | 5.15 | 5.15 |
| Pacific Biosciences of California, Inc. (PACB)vs › | $843.28M | 4.03 | 6.29 | 5.71 | 7.79 |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $951.98M | 11.36 | 7.20 | 7.20 | 7.20 |
| MoonLake Immunotherapeutics (MLTX)vs › | $947.98M | 12.56 | 15.19 | 22.99 | 17.56 |
Quick Ratio
1.17
Excludes inventory
Current Ratio
1.69
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-27 | 1.17 |
| 2026-03-28 | 1.13 |
| 2025-12-31 | 1.19 |
| 2025-09-27 | 1.14 |
| 2025-06-28 | 0.96 |
| 2025-03-29 | 0.89 |
| 2024-12-31 | 0.87 |
| 2024-09-28 | 0.99 |
| 2024-06-29 | 0.96 |
| 2024-03-30 | 0.97 |
| 2023-12-31 | 1.01 |
| 2023-09-30 | 0.94 |
| 2023-07-01 | 0.92 |
| 2023-04-01 | 1.13 |
| 2022-12-31 | 0.62 |
| 2022-10-01 | 0.67 |
| 2022-07-02 | 1.05 |
| 2022-04-02 | 1.05 |
| 2021-12-31 | 1.11 |
| 2021-10-02 | 1.30 |
| 2021-07-03 | 1.62 |
| 2021-04-03 | 1.55 |
| 2020-12-31 | 1.49 |
| 2020-09-30 | 1.42 |
| 2020-06-30 | 2.06 |
| 2020-03-28 | 0.00 |
| 2019-12-06 | 1.75 |
| 2019-12-06 | 0.00 |
| 2019-06-29 | 0.00 |
| 2019-03-29 | 0.00 |
| 2016-03-31 | 0.72 |
| 2015-03-31 | 0.00 |
